Filing Flows › Voyager Therapeutics (VYGR) › Recalls, complaints & regulation

Voyager Therapeutics (VYGR): clinical trials

Voyager Therapeutics (VYGR) beyond its filings: 2 active clinical trials.

Voyager Therapeutics' latest quarter

Voyager Therapeutics, Q3 2026: revenue $4.0M (-70% year over year), operating margin -658.2%, net loss $24.7M, operating cash flow −$19.7M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Voyager Therapeutics have?

2 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.